This inventor holds 91 USPTO granted patents and 15 published patent applications, plus 4 CIPO patents and 14 EPO patents, primarily in Pharmaceutical Compounds (CPC class A61P3-10). Top assignees: Janssen Pharmaceutica Nv, Ortho-Mcneil Pharmaceutical Corp., Ohmeda Pharmaceutical Products Division Inc.. Active years: 1995-2026.
Inventors with similar research interests:
Location History:
- New Brunswick, NJ (US) (2004)
- Raritan, NJ (US) (2007)
- Branchburg, NJ (US) (1995 - 2014)
- Cranbury, NJ (US) (2012 - 2014)
- Spring House, PA (US) (2012 - 2017)
- Gwynedd, PA (US) (2017)
- Gwynedd Valley, PA (US) (2013 - 2023)
- Lower Gwynedd, PA (US) (2014 - 2023)
Company Filing History:
75 out of 2,099 
11 out of 363 
4 out of 7 Years Active: 1995-2026
Areas of Expertise:
Title: Mark J Macielag: Pioneering Innovations in Pharmaceutical Research
Introduction:
Mark J Macielag, a renowned inventor based in Gwynedd Valley, PA, has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 88 patents. His innovative work focuses on developing solutions for thromboembolic disorders, inflammatory diseases, and neuropeptide Y receptor modulation.
Latest Patents:
Mark J Macielag's latest patents include groundbreaking inventions such as Pyridine N-oxide derivatives used as factor XIa inhibitors. These compounds have shown promise in treating thromboembolic disorders and inflammatory conditions by targeting plasma kallikrein activity. Additionally, his work on antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors opens up new possibilities for treating various diseases and disorders.
Career Highlights:
Mark J Macielag has honed his expertise through notable tenures at esteemed companies such as Janssen Pharmaceutica NV and Ortho-McNeil Pharmaceutical Corp. His leadership and innovative approach have been instrumental in driving forward cutting-edge research and development in the pharmaceutical industry, leading to numerous breakthroughs in drug discovery and treatment methodologies.
Collaborations:
Throughout his career, Mark J Macielag has collaborated with talented professionals in the field, including esteemed colleagues such as Yue-Mei Zhang and Bin Zhu. These collaborations have not only enriched his work but have also fostered a culture of innovation and collaboration that has propelled the advancement of pharmaceutical research.
Conclusion:
In conclusion, Mark J Macielag stands as a beacon of innovation in the pharmaceutical industry, with a rich tapestry of patents and inventions that have the potential to revolutionize healthcare. His dedication to pushing boundaries and seeking novel solutions underscores his commitment to making a lasting impact on the world of medicine.